



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of: **Cohn et al**

Application No: **09/658,261**

Group Art Unit: **1614**

Filed: **September 8, 2000**

Examiner: **R. J. Henley III**

TECH CENTER 1600/2900
MAY 08 2002

#11A
2/15/02
RECEIVED

For: **Methods of Treating and Preventing Congestive Heart Failure with Hydralazine Compounds and Isosorbide Dinitrate or Isosorbide Mononitrate**

Attorney Docket No: **102258.288**

Assistant Commissioner of Patents
Washington, DC 20231

RESPONSE AND AMENDMENT UNDER 37 C.F.R. § 1.111

This Response is submitted in reply to the Office Action dated December 5, 2001, for which a response is due on or before May 6, 2002 (the first business day after May 5, 2002). The Commissioner is authorized to charge the two-month extension of time fee of \$200 to Deposit Account No. 08-0219. The Commissioner is authorized to charge any other necessary fees to Deposit Account No. 08-0219 to maintain the pendency of the present application.

Please amend the present application, without prejudice, as follows.

IN THE CLAIMS:

Attached hereto as Appendix 1 is a copy of the pending claims. Attached hereto as Appendix 2 is a copy of the amended claims.

IN THE SPECIFICATION:

Attached hereto as Appendix 3 is a copy of the amended specification. Attached hereto as Appendix 4 is copy of the amendments made to the specification.

I. Remarks

After entry of the amendment, claims 1-50 are pending.

The specification and claim 2 have been amended to correct typographical errors.

A